CMCD provides and continues to develop tests that are specific to the unique needs of women’s health. Women today have many things to be concerned with and we believe the quality and capability of their testing should not be one of them.
We know that the earlier a cancer or cancer precursor can be detected, the better the chances of cure and survival. That places our focus on screening test that enable the physician to work confidently with their patient.
Along with other tests to assist physicians in the identification and treatment of cancers, CMCD has developed the CompDx hrHPV genotype test. This next generation test, coupled with the liquid based Pap testing provides the most and best possible information for the monitoring and treatment decisions used with your patient.